1. Vezér B, Buzás Z, Sebeszta M, et al. Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents. Curr Med Res Opin. 2016;32(5):829–34.
2. European Medicines Agency. Remicade®: procedural steps taken and scientific information after authorization.
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Procedural_steps_taken_and_scientific_information_after_authorisation/human/000240/WC500050890.pdf
. Accessed 20 Nov 2017.
3. European Medicines Agency; European Commission. Biosimilars in the EU: information guide for health care professionals.
http://www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2017/05/WC500226648.pdf
. Accessed 28 Sep 2017.
4. US Food and Drug Administration. Biological product definitions.
https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/UCM581282.pdf
. Accessed 6 Nov 2017.
5. Dos Reis C, Teixo R, Mendes F, Cruz RS. Biosimilar medicines: review. Int J Risk Saf Med. 2016;28(1):45–60.